Aprea Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$13.2M | -$14.3M | -$15.5M | -$113.4M | -$37.4M |
| Operating expenses | $13.5M | $15.8M | $16.1M | $113.4M | $37.4M |
| Cash from operations | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M |
| Capital expenditure | — | $15,478 | $93,093 | — | — |
| Free cash flow | — | -$13.6M | -$12.3M | — | — |
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M |
| Total liabilities | — | — | — | $3.2M | $7.3M |
Shares outstanding 12.4M · Free float 65.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.